5 citations
,
April 2024 in “JAAD International” AI can accurately measure hair loss severity in alopecia areata.
November 2025 in “Turkish Journal of Dermatology” In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.
November 2024 in “SKIN The Journal of Cutaneous Medicine” This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.
January 2024 in “JEADV clinical practice” This article reviews how SALT scores are used in clinical trials for alopecia areata and provides patient images to help clinicians understand and apply these scores in practice; it reports no new clinical results.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.